GMT Stock Overview
Genomtec S.A. manufactures mobile molecular analyzers using molecular diagnostics technology worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||zł6.99|
|52 Week High||zł14.98|
|52 Week Low||zł6.00|
|1 Month Change||-1.83%|
|3 Month Change||-29.04%|
|1 Year Change||-52.06%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-48.41%|
Recent News & Updates
|GMT||PL Biotechs||PL Market|
Return vs Industry: GMT underperformed the Polish Biotechs industry which returned -40% over the past year.
Return vs Market: GMT underperformed the Polish Market which returned -15.6% over the past year.
|GMT Average Weekly Movement||8.7%|
|Biotechs Industry Average Movement||8.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in PL Market||14.8%|
|10% least volatile stocks in PL Market||5.1%|
Stable Share Price: GMT is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: GMT's weekly volatility (9%) has been stable over the past year.
About the Company
Genomtec S.A. manufactures mobile molecular analyzers using molecular diagnostics technology worldwide. The company’s flagship mobile diagnostic platform is Genomtec ID, a diagnostic device that is based on the amplification and detection of specific DNA and RNA fragments. Its Genomtec ID analyzer allows the company to test and diagnose viruses, bacteria, mutations, fungi, and parasite infections.
Genomtec Fundamentals Summary
|GMT fundamental statistics|
Is GMT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GMT income statement (TTM)|
|Cost of Revenue||zł673.26k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 27, 2022
|Earnings per share (EPS)||-0.65|
|Net Profit Margin||-2,410.43%|
How did GMT perform over the long term?See historical performance and comparison
Is Genomtec undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GMT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GMT's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: GMT is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.
PE vs Market: GMT is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GMT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GMT is overvalued based on its PB Ratio (23x) compared to the PL Biotechs industry average (4.5x).
How is Genomtec forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genomtec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Genomtec performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GMT is currently unprofitable.
Growing Profit Margin: GMT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if GMT's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare GMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: GMT has a negative Return on Equity (-212.77%), as it is currently unprofitable.
How is Genomtec's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GMT's short term assets (PLN2.3M) exceed its short term liabilities (PLN1.2M).
Long Term Liabilities: GMT's short term assets (PLN2.3M) do not cover its long term liabilities (PLN3.0M).
Debt to Equity History and Analysis
Debt Level: GMT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GMT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GMT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GMT has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.3% each year.
What is Genomtec current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GMT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Mr. Miron Tokarski, PhD, is Chief Executive Officer, Member of the Management Board and Co-founder of Genomtec S.A. His responsibilities within the company involve, among others, R & D and development of i...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genomtec S.A.'s employee growth, exchange listings and data sources
- Name: Genomtec S.A.
- Ticker: GMT
- Exchange: WSE
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł57.028m
- Shares outstanding: 8.16m
- Website: https://www.genomtec.com
Number of Employees
- Genomtec S.A.
- ul. Stablowicka 147
- PORT Budynek 2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.